PATENT CLAIM ANALYSIS

Application Number: 16057766
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-11
Patent Classification: ["424", "141100"]

Abstract:
The present invention provides antibodies that bind to human GFRα3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFRα3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFRα3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.

Claim (Index 7):
The isolated monoclonal antibody or an antigen-binding fragment thereof of  claim 4 , wherein the antibody or the antigen-binding fragment thereof blocks or inhibits artemin-dependent activation of human RET with an IC 50  ranging from about 300 pM to about 5 nM.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 96.0
- Lexical Diversity: 1.78049
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15382256', '14577362', '13971965', '14717760', '15621689']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8441466706497757
- 35 USC 102 Novelty (BERT): 0.6433735037308648
- Combined Prediction Score: 0.8240693539578846
- Mean Citation Score: 618.217626
- Max Citation Score: 790.70087
- Similarity Product: 554.958069086883

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test